Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2003

View Archived Issues

Licofelone downregulates PMN/platelet function in vitro

Single-agent epratuzumab trial closes

RG-2133 enters phase I/II for bipolar disorder and major depression

Pharmacia claims new alpha7 nicotinic agonists for schizophrenia and cognitive dysfunction

AIDS vaccine developed at Emory and NIH enters clinical testing

Celera Genomics and Aventis jointly develop novel cathepsin S inhibitors

New integrin antagonists with utility in asthma covered by Aventis patent

Roche scientists prepare and test new 5-HT6 agonists

Lilly claims antitumor benzoylsulfonamides and sulfonylbenzamidines

Nippon Soda reports novel cGMP-PDE inhibitors with potential as vasodilators

Sato patent covers antibacterial quinolizinones

FR-167653 as a potential new therapy for endotoxemia

Further evidence supporting PARP inhibition as a therapeutic target in circulatory shock

Clinical testing of new PPARgamma agonist from Tularik commences

Rights to cantuzumab mertansine returned to ImmunoGen

HuMax-CD4 enters phase II clinical studies for CTCL

Clearance received in U.S. for efficacy trials of Helivax

Ketek deemed approvable by the FDA for respiratory tract infections

Abbott begins supplying Humira to pharmacies within a week of approval

Nastech reacquires rights to intranasal product for sexual dysfunction

BMS-207940: a second-generation ETA receptor antagonist with a favorable pharmacokinetic profile

CB1 receptor-mediated discriminative stimulus effects of Bay-38-7271

Naltrexone well tolerated and effective in pruritus caused by cholestasis

New data on once-daily lonafarnib in patients with advanced solid tumors

Improved bone mineral density found for teriparatide in male patients with osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...